Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRBP NASDAQ:CRDL NASDAQ:GBIO NASDAQ:HURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBPCorbus Pharmaceuticals$7.70+1.9%$9.78$6.72▼$20.56$142.68M2.57312,472 shs293,532 shsCRDLCardiol Therapeutics$1.08$1.33$0.88▼$1.71$124.47M0.72543,214 shs334,106 shsGBIOGeneration Bio$5.34$5.48$3.00▼$6.95$35.99M2.05160,744 shsN/AHURATuHURA Biosciences$2.02-1.5%$2.28$0.41▼$3.90$128.63M0.011.33 million shs390,863 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBPCorbus Pharmaceuticals0.00%-2.45%-31.02%-24.70%-18.09%CRDLCardiol Therapeutics-2.70%-11.48%-18.18%+1.89%-23.40%GBIOGeneration Bio0.00%0.00%0.00%0.00%+22.48%HURATuHURA Biosciences+3.81%-8.71%-14.08%+13.61%-27.22%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBPCorbus Pharmaceuticals$7.70+1.9%$9.78$6.72▼$20.56$142.68M2.57312,472 shs293,532 shsCRDLCardiol Therapeutics$1.08$1.33$0.88▼$1.71$124.47M0.72543,214 shs334,106 shsGBIOGeneration Bio$5.34$5.48$3.00▼$6.95$35.99M2.05160,744 shsN/AHURATuHURA Biosciences$2.02-1.5%$2.28$0.41▼$3.90$128.63M0.011.33 million shs390,863 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBPCorbus Pharmaceuticals0.00%-2.45%-31.02%-24.70%-18.09%CRDLCardiol Therapeutics-2.70%-11.48%-18.18%+1.89%-23.40%GBIOGeneration Bio0.00%0.00%0.00%0.00%+22.48%HURATuHURA Biosciences+3.81%-8.71%-14.08%+13.61%-27.22%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBPCorbus Pharmaceuticals 2.75Moderate Buy$42.00445.45% UpsideCRDLCardiol Therapeutics 2.33Hold$8.50687.04% UpsideGBIOGeneration Bio 2.29Hold$8.8866.20% UpsideHURATuHURA Biosciences 2.67Moderate Buy$9.00345.54% UpsideCurrent Analyst Ratings BreakdownLatest GBIO, CRBP, HURA, and CRDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026CRBPCorbus Pharmaceuticals WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$38.00 ➝ $30.005/26/2026CRBPCorbus Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/26/2026CRBPCorbus Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.005/22/2026CRBPCorbus Pharmaceuticals MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$40.00 ➝ $44.005/13/2026CRBPCorbus Pharmaceuticals OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$57.00 ➝ $54.005/13/2026CRBPCorbus Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.005/12/2026CRBPCorbus Pharmaceuticals Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$36.00 ➝ $33.004/29/2026CRBPCorbus Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.004/29/2026CRBPCorbus Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.004/27/2026HURATuHURA Biosciences CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform4/27/2026HURATuHURA Biosciences Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$9.00(Data available from 6/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBPCorbus PharmaceuticalsN/AN/AN/AN/A$8.40 per shareN/ACRDLCardiol TherapeuticsN/AN/AN/AN/A$0.11 per shareN/AGBIOGeneration Bio$19.89M1.81N/AN/A$12.91 per share0.41HURATuHURA BiosciencesN/AN/AN/AN/A$0.34 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBPCorbus Pharmaceuticals-$78.54M-$5.82N/AN/AN/AN/A-70.89%-61.78%8/11/2026 (Estimated)CRDLCardiol Therapeutics-$24.20M-$0.28N/AN/AN/AN/A-229.43%-165.60%8/13/2026 (Estimated)GBIOGeneration Bio-$131.67M-$9.34N/AN/AN/A-410.13%-94.82%-34.13%N/AHURATuHURA Biosciences-$30.05M-$0.61N/AN/AN/AN/A-156.12%-105.38%8/13/2026 (Estimated)Latest GBIO, CRBP, HURA, and CRDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026HURATuHURA Biosciences-$0.12-$0.13-$0.01-$0.13N/AN/A5/12/2026Q1 2026CRBPCorbus Pharmaceuticals-$1.26-$1.23+$0.03-$1.23N/AN/A5/11/2026Q1 2026CRDLCardiol Therapeutics-$0.07-$0.07N/A-$0.07N/AN/A3/31/2026Q4 2025HURATuHURA Biosciences-$0.1233-$0.13-$0.0067-$0.10N/AN/A3/30/2026Q4 2025CRDLCardiol Therapeutics-$0.09-$0.05+$0.04-$0.05N/AN/A3/9/2026Q4 2025CRBPCorbus Pharmaceuticals-$1.78-$1.25+$0.53-$1.25$1.11 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRBPCorbus PharmaceuticalsN/AN/AN/AN/AN/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/AGBIOGeneration BioN/AN/AN/AN/AN/AHURATuHURA BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBPCorbus PharmaceuticalsN/A7.927.92CRDLCardiol TherapeuticsN/A4.394.39GBIOGeneration BioN/A4.444.44HURATuHURA BiosciencesN/A1.151.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBPCorbus Pharmaceuticals64.64%CRDLCardiol Therapeutics12.49%GBIOGeneration Bio95.22%HURATuHURA Biosciences0.62%Insider OwnershipCompanyInsider OwnershipCRBPCorbus Pharmaceuticals3.50%CRDLCardiol Therapeutics5.25%GBIOGeneration Bio21.10%HURATuHURA Biosciences0.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRBPCorbus Pharmaceuticals4018.53 million17.88 millionOptionableCRDLCardiol Therapeutics20115.25 million109.20 millionNot OptionableGBIOGeneration Bio1506.74 million5.32 millionOptionableHURATuHURA BiosciencesN/A63.68 million63.56 millionN/AGBIO, CRBP, HURA, and CRDL HeadlinesRecent News About These CompaniesTuHURA Biosciences, Inc. (NASDAQ:HURA) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 4, 2026 | americanbankingnews.comBrookline Capital Markets Estimates HURA Q2 EarningsJune 1, 2026 | americanbankingnews.comTuHURA Biosciences (NASDAQ:HURA) Rating Lowered to "Sell" at Wall Street ZenMay 31, 2026 | americanbankingnews.comTuHURA Biosciences Draws on New $50M Credit FacilityMay 29, 2026 | tipranks.comHURA: Refining TBS-2025 development planMay 26, 2026 | msn.comTuHURA Biosciences, Inc.: TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateMay 16, 2026 | finanznachrichten.deTuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateMay 15, 2026 | prnewswire.comTuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor ConferenceMay 12, 2026 | prnewswire.comTuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 10, 2026 | marketbeat.comCitizens Initiates Coverage of TuHURA Biosciences (HURA) with Market Outperform RecommendationApril 28, 2026 | msn.comTuHURA Biosciences Secures $50 Million Credit FacilityApril 22, 2026 | tipranks.comTuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028April 22, 2026 | prnewswire.comWhy TuHURA Biosciences, Inc.’s (HURA) Stock Is Down 5.48%April 20, 2026 | aaii.comAIs TuHURA Biosciences (HURA) One of the Unstoppable Stocks That Could Double Your Money?April 20, 2026 | finance.yahoo.comTuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical OperationsApril 7, 2026 | prnewswire.comTuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate UpdateApril 1, 2026 | prnewswire.comCraig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related CancersMarch 23, 2026 | prnewswire.comTuHURA Biosciences (NASDAQ:HURA) Trading Down 3.1% – Here’s WhyMarch 14, 2026 | defenseworld.netDTuHURA Biosciences, Inc.: TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price RequirementFebruary 27, 2026 | finanznachrichten.deTuHURA Biosciences stock gains after Nasdaq complianceFebruary 27, 2026 | za.investing.comTuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price RequirementFebruary 27, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGBIO, CRBP, HURA, and CRDL Company DescriptionsCorbus Pharmaceuticals NASDAQ:CRBP$7.70 +0.14 (+1.85%) Closing price 04:00 PM EasternExtended Trading$7.84 +0.14 (+1.81%) As of 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.Cardiol Therapeutics NASDAQ:CRDL$1.08 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.08 0.00 (0.00%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.Generation Bio NASDAQ:GBIOGeneration Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.TuHURA Biosciences NASDAQ:HURA$2.02 -0.03 (-1.46%) Closing price 04:00 PM EasternExtended Trading$1.89 -0.13 (-6.63%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Corning Is Paving AI's Future With Glass The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning? Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking? From Crypto to AI: Insiders Are Trading These 3 Stocks The Case for Intel Over Pure-Play Quantum Firms Has Temu-Owner PDD's Story Changed After Double Miss? Campbell's Soup Stock: Deep Value and a 7% Dividend Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
